Stocks · News reference
GeneDx Holdings Affirms FY2026 Sales Guidance of $475.000M-$490.000M vs $482.324M Est
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Groupon Posts Downbeat Q3 Results, Joins GeneDx Holdings, Qualys And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
Groupon plunged 20% premarket after missing quarterly earnings and sales estimates, while Digital Turbine, Daqo and others also traded lower.
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Co-Diagnostics (NASDAQ:CODX) stock moved upwards by 22.4% to $0.39 during Tuesday's pre-market session. The company's market cap stands at $2.8 million. As per the press release, Q3 earnings came out
GeneDx Holdings Q3 2026 Earnings Call Transcript
GeneDx Holdings (NASDAQ:WGS) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs.
GeneDx Holdings Corp. Reports Q3 2026 Financial Results
GeneDx Holdings Corp. announced its third-quarter 2026 financial results, reporting revenue of $123.1 million and adjusted earnings per share of $0.28.
8-K filing — GeneDx Holdings Corp. (WGS)
Filed: 2026-11-09 AccNo: 0001628280-26-072172 Size: 6 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits